Skip to main content
Published Online:https://doi.org/10.3928/0090-4481-19931201-08
First page image

  • 1. Whilley RJ, Gnann JW. The epidemiology and clinical manifestations of herpes simplex virus infections, in: Roizman B, Whitlty RJ, Lopez C, eds. The Human Herpesviruses. New York, NY: Raven Press; 1993:69-105.

    Google Scholar
  • 2. Andrews CH, Carmichael EA. A note on the presence of antibodies to hetpesvirus in post-encephalitic and other human sera. Lancet. 1930;l:857-858.

    Google Scholar
  • 3. Burke RL Current status of HSV vaccine development. In: Roizman B, Whitley RJ, Lopei C. eds. The Human Herpesvmaes. New York, NY: Raven Press; 1993:367-379.

    Google Scholar
  • 4. Teissler P, Gastinel R Reilly J. L'inoculabiliie de l'herpes: presence du virus keiatogene dans les lesions. Comptes Renati des Seances de la Société de Biologe et des ses Filial«, 1922:87:648.

    Google Scholar
  • 5. Hall MJ, Katrak K. The quest for a herpes simplex virus vaccine: background and recent development. Vaccine. 1986;4:138-150.

    Google Scholar
  • 6. Meignier B. Vaccination against herpes simplex virus infections. In: Ruizman B, Lope: C, eds. The Herpesviruses. Immunobiology and Prophylaxis of Human Herpesvirus Infections. New fork, NY: Plenum Press; 1985:265-290.

    Google Scholar
  • 7. Burke RL, Nest GV, Carlion ], et al. Development of herpes simplex virus subunit vaccine. Vaccinia 89, New York, NY: Cold Spring Harbor Laboratory; 1989.

    Google Scholar
  • 8. Corey L, Dekker C, Adair S, Sekulovich R, Butte RL. A highly immunogeoic tecombinant HSV-2 glycoprotein vaccine: gD2 and gB2 in the miccrofluidized adjuvant MF- 59. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Octobe 1 11-14, 1992; Anaheim. Calif.

    Google Scholar
  • 9. Berman PW, Dowbenco O, Lasky LA, Simonsen CC. Detection of antibodies to herpes simplex virus with a continuous cell line expressing cloned glycoprotein D. Science. 1983;222:524-527.

    Google Scholar
  • 10. Smith GL, Macltett M, Moss B. Infectious vaccinia vims «combinants chat express hepatitis 8 virus surface antigen. Nature. 1983:302:490-495.

    Google Scholar
  • 11. Roizman B, Jenkins FJ. Genetic engineering of novel genomes of large DNA viruses. Science. 1985;229:J208-12I4.

    Google Scholar
  • 12. Meignier B, Longnecker R, Roiiman B. In vivo behavior of genetically engineered herpes simplex virus R7017 and R7020. Construction and evaluation in rodents. } Infect Dis. 1988:1 58:602-614.

    Google Scholar
  • 13. Meignier B, Martin B, Whidey R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020, IL studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Inject Dis. 1990;162;313-321.

    Google Scholar
  • 14. Cadoi M, Micoud M, Seigneutin JM, et al. Phase 1 trial of R7020: a live attenuated recombinant herpes simplex (HSV) candidate vaccine. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11-14. 1992; Anaheim, Calif.

    Google Scholar
  • 15. Whitlev RJ. Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of latency, and induced reactivation of iierpes simplex virus 3"f.5 deletion mutants in rodent models. J Ciminosi. 1993i91:2837-2843.

    Google Scholar

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×
  • Published online12/1/93 12:00 AM
  • __article__history--ppub12/1/93 12:00 AM